This report takes a look at both prevention procedures such as sterilization and surface area disinfection and testing such as molecular tests and immunoassays. Infection control in healthcare facilities deals largely with protecting building occupants from patients with communicable infectious diseases. Infections, which may result from activities and procedures taking place within the facility, have become a cause for great concern. Infection that is acquired during the course of healthcare is known as a nosocomial, or hospital acquired, infection.
What is the size of the market for healthcare infections testing and prevention? What are the top companies in the market? What is the expected growth in the future? The scourge of healthcare-associated infections or hospital acquired infections, or HAIs, is a real concern for healthcare providers. They stand to lose profit and contribute to negative patient outcomes if they do not control these infections. This has created market for three types of products, products to prevent, products to test for disease and then treatment products. This report deals with the first two, and looks how the markets interplay.
In some European countries, including the United Kingdom, screening for aggressive infections such as MRSA is performed in many hospitals upon admission.
As part of its coverage, this report includes:
Markets for HAI Testing and HAI Prevention, 2016-2021
Description of Infections
Hospital Spending Priorities
Cost of HAIs
The Basics - About Nosocomial Infections (HAIs)
Prevention Segments for Disinfectants, Sterilization and Wide Area Disinfection
The Prevention Effect
Testing Segments - Immunoassays, Molecular, Microbiology
Important Conclusions about the Market
The infection may occur in a postoperative wound or as a complication unrelated to the disease or condition. The U.S. Centers for Disease Control and Prevention (CDC) estimates that around 1 in 20, or 5%, of hospitalized patients will contract an HAI. Worldwide, the rate of nosocomial infections is between 3.5% and 12% of admissions in developed regions.
The prevention market consists of technologies and consumables to reduce the risk of infection transmission. These include:
Heat/steam sterilization systems
Chemical sterilization systems and consumables
Radiation sterilization technologies
Sterilization verification system
The testing market includes the use of diagnostic equipment and consumables to detect infections and determine the best treatment plan. These include:
Microbial identification and sensitivity tests
Molecular and DNA tests
To prevent infection, all possible measures are taken to create and maintain a therapeutic environment for the patient and healthcare workers.
In recent years, there have been improved methods for testing infected patients. For example, testing for MRSA infections can be done via a nostril swab, now an effective option in detecting bacteria. Admission screening has been effective in some areas and has reduced the spread of MRSA infections in hospitals in the United States and some European countries.